NEW YORK, July 20, 2026 — Shares of Tempus AI, Inc. (NASDAQ:TEM) fell sharply on Monday, declining 7.8% to $48.39 after touching an intraday low of $47.11. The move brought the stock within striking distance of the $46 reference price outlined in regulatory filings, a level that could allow acquisition partner Personalis, Inc. (NASDAQ:PSNL) to exercise a termination right under the merger agreement.
The decline erased approximately $730 million from Tempus's market capitalization, which stood at $8.67 billion by the close. That reduction represents nearly half of the transaction's $1.5 billion net enterprise value, underscoring the market's sensitivity to the stock-based deal structure.
Deal Mechanics and Market Reaction
According to Tempus's SEC filing, if the stock price falls below $46 before the transaction closes, Personalis may have the right to terminate the agreement. At Monday's closing price, Tempus traded just 5.2% above that critical threshold, while the intraday low was only 2.4% higher. The narrowing gap has heightened uncertainty around the deal's completion.
Under the terms, Personalis shareholders would receive Tempus stock, with a maximum exchange ratio of 0.3356 Tempus shares per Personalis share. Tempus also retains the option to pay up to half of the consideration in cash. At Monday's quoted price, the maximum full-stock ratio equated to approximately $16.24 per Personalis share, just one cent below the headline offer price of $16.25. When Tempus hit its intraday low of $47.11, the value fell to $15.81.
Personalis Shares Under Pressure
Personalis shares also suffered, dropping 12.7% to $13.44, a 17.3% discount to the announced offer price. Guggenheim analyst Subbu Nambi attributed the declines to the largely stock-based nature of the deal and lingering doubts among Personalis investors about Tempus's future growth prospects.
The strategic rationale for the merger centers on expansion in the molecular residual disease (MRD) market. Personalis recently reported estimated second-quarter revenue of $22.4 million, with clinical tests totaling 10,384 — a 33% quarter-over-quarter increase. Annualizing that revenue yields approximately $89.6 million, making the $1.5 billion net enterprise value roughly 16.7 times that run rate, though seasonality and revenue composition complicate direct comparisons.
Tempus, for its part, trades at a price-to-sales ratio of about 5.4 based on the midpoint of its 2026 revenue guidance of $1.595 billion. Tempus CEO Eric Lefkofsky noted that the company waited for Personalis to achieve "a really healthy business" in terms of margins before pursuing the deal. Tempus anticipates that expanded reimbursement and sales coverage will drive volume growth. Roughly 10% of Tempus's sales team is currently focused on selling the NeXT Personal Dx test, and the company estimates the U.S. MRD market is worth over $20 billion.
Broader Market Context
The decline in Tempus and Personalis shares outpaced comparable stocks. Guardant Health (NASDAQ:GH) fell 4.2%, while Natera (NASDAQ:NTRA) slipped 2.1%, suggesting deal-specific pressure rather than sector-wide weakness.
Tempus is scheduled to report second-quarter results on July 30, which will provide an update on liquidity and forward guidance. The company maintains an adjusted EBITDA target of approximately $65 million for 2026. However, risks remain: the transaction requires approval from Personalis shareholders and regulators, and factors such as reimbursement changes, integration challenges, borrowing costs, and dilution could impact profitability. A continued decline in Tempus shares would add further uncertainty to the deal's completion.
Investors are awaiting the S-4 and Schedule 13E-3 filings for more detailed terms. For now, the $46 benchmark and the 0.3356 exchange cap remain the most clearly defined public terms of the transaction.
